BREZTRI: cost and payments to doctors
What Medicare Part D paid pharmacies for BREZTRI, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Part D cost for BREZTRI formulations
Medicare reports BREZTRI under its specific formulations, which are priced separately.
- breztri aerosphere$612per 30-day fill · 1,165,471 claims · Budesonide/Glycopyr/Formoterol
Paid to pharmacies by Part D plans and patients — not your cost, and not paid to the prescriber. Is this wrong?
Was your doctor paid by AstraZeneca?
AstraZeneca reported the most payments naming BREZTRI. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $29.9M
- Providers
- 87,308
- Transactions
- 453,113
- Average per transaction
- $66
The per-transaction average — $66 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 87,308 providers the average total is $343, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| AstraZeneca | $29,443,694 | 98.4% |
| Astrazeneca UK Limited | $481,514 | 1.6% |
| Astrazeneca AB | $4,028 | 0.0% |
| Acerta Pharma LLC | $2,996 | 0.0% |
Other products from AstraZeneca
The company that reported the most payments naming BREZTRI also reports against these.